Activist investor William Ackman -- who worked closely with Valeant CEO last year during Valeant's failed takeover attempt of Allergan -- holds 8.4 percent of Zoetis shares. Shares of Zoetis rose 11 percent -- reaching the highest price the stock has been since it began trading in 2013.